Mode
Text Size
Log in / Sign up
N/A N=1,001

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

Acute Kidney Injury

Enrolled (actual)
1,001
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting. — 0.671 Probability

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Abbott RDx Cardiometabolic
Primary completion
Apr 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
The Efficacy of the Triage Neutraphil-Gelatinase Associated Lipocalin (NGAL) Test as an Aid in the Diagnosis of Acute Kidney Injury (AKI) in an All-comers ICU Setting.
0.671

Summary

This is a multi-center, prospective, observational study of patients that are admitted to the intensive care unit (ICU). This study does not include any treatment or intervention and it is considered Nonsignificant Risk.

Eligibility Criteria

Inclusion Criteria

  • Subjects must be 21 years of age or older.
  • Subjects must be admitted to an Intensive Care Unit (medical or surgical) and must be enrolled into this study within 12 hours of receipt of ICU admission orders.
  • Subjects must be assessed as likely to be alive in the ICU for a minimum of 48 hours after enrollment.
  • The following plasma/serum creatinine values must be available:
  • Subjects that are admitted to the ICU following an elective surgery or procedure must have at least one pre-surgical/ pre-procedure creatinine value obtained in the 7 days prior to presentation to the ICU.
  • Subjects that are admitted to the ICU for any reason other than following an elective surgery or procedure must have at least one creatinine value obtained greater than 7 days and up to 6 months prior to presentation to the ICU.

Exclusion Criteria

  • Subjects either receiving or in imminent need of Renal Replacement Therapy.
  • Subjects with evidence of chronic kidney disease stages 4 and 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL/min/1.73M2 (according to the 4-variable MDRD22).
  • Subjects with any obstructive uropathy at the time of presentation to the ICU.
  • Subjects with any known urothelial, urological or kidney malignancies.
  • Subjects that have had any urologic procedure or surgery immediately prior to admission to the ICU.
  • Subjects that have had any renal transplant or nephrectomy.
  • Subjects that have had cardiovascular surgery involving cardiopulmonary bypass within the previous 7 days.
  • Subjects that have participated in an interventional clinical study within the previous 30 days including studies with any investigational and non-investigational drugs.
  • The inability to obtain written Informed Consent from the subject or an authorized representative.
  • Subjects that have been previously enrolled in this study during a prior admission to the ICU.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01294228). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search